依米康(300249.SZ):已成功完成浸沒式液冷產品的開發,並在中東地區成功投運首臺套NetLiq2002.0液冷升級版產品
格隆匯6月16日丨依米康(300249.SZ)於近期投資者關係活動表示,公司已成功完成浸沒式液冷產品的開發,並在中東地區成功投運首臺套NetLiq2002.0液冷升級版產品;繼液冷集裝箱於中東成功投運後,公司持續開發基於風冷、水冷等多種室外散熱形式的冷板、浸沒式液冷整體解決方案,包括:液冷整套系統解決方案及配套的液冷控制系統、液冷運維繫統等,實現客戶液冷從建設到運維的整體解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.